SCHEMBL1686595

SCHEMBL1686595

Cc1cc(C)c(C)c([Si](O)(O)O)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 2/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
ACHE P22303 1/20 0.36
RAPGEF4 Q8WZA2 2/20 0.35
TP53 P04637 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
MMP1 P03956 1/20 0.31
MMP2 P08253 1/20 0.31
MMP9 P14780 1/20 0.31
MMP8 P22894 1/20 0.31
MMP13 P45452 1/20 0.31
SELL P14151 1/20 0.31
SELP P16109 1/20 0.31
SELE P16581 1/20 0.31
NOS3 P29474 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1686592 0.85 ALDH1A1 (0.39) ALDH1A1KDM4ELMNAGAAMAPT
SCHEMBL28033805 0.77 IDO1 (0.41) ALDH1A1KDM4ELMNAGAAMAPT
SCHEMBL1686795 0.77 CYP1A2 (0.34)
SCHEMBL16707372 0.75 RAPGEF4 (0.35) ALDH1A1KDM4ELMNAGAAMAPT
SCHEMBL10321719 0.73 MAPT (0.33) ALDH1A1KDM4ELMNAGAAMAPT
SCHEMBL13027082 0.71 ACHE (0.34) ALDH1A1KDM4ELMNAGAAMAPT
SCHEMBL28951 0.71 RAPGEF4 (0.59) ALDH1A1KDM4ELMNAGAAMAPT
SCHEMBL1551822 0.71 RAPGEF4 (0.59) ALDH1A1KDM4ELMNAGAAMAPT
SCHEMBL1686721 0.70 ALDH1A1 (0.44) ALDH1A1KDM4ELMNAGAAMAPT
SCHEMBL1686578 0.70 TDP1 (0.48) ALDH1A1KDM4ELMNAGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932330-B2 Process for producing modified particle; carrier; catalyst component for addition polymerization; process for producing catalyst for addition polymerization; and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-04-26 US disclosed
US-7592402-B2 Process for producing modified particle; carrier; catalyst component for addition polymerization; process for producing catalyst for addition polymerization; and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-09-22 US disclosed
US-20080319148-A1 Process for producing modified particle; carrier; catalyst component for addition polymerization; process for producing catalyst for addition polymerization; and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED 2008-12-25 US disclosed
US-7115539-B2 Metal compound, and catalyst component and catalyst for addition polymerization, and process for producing addition polymer SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2006-10-03 US disclosed
US-20050245701-A1 Process for producing modified particle; carrier; catalyst component for addition polymerization; process for producing catalyst for addition polymerization; and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED 2005-11-03 US disclosed
US-20040209762-A1 Metal compound, and catalyst component and catalyst for addition polymerization, and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED 2004-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209762-A1 Metal compound, and catalyst component and catalyst for addition polymerization, and process for producing addition polymer AP1M1, PYM1, SEM1 ALDH1A1 1378/4885KDM4E 1556/4885LMNA 1707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.